BiotechTube

CMV-pp65 CTLs

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cytomegalovirus

Conditions

Cytomegalovirus

Trial Timeline

Jul 13, 2012 → Dec 11, 2019

NCT ID
NCT01646645

About CMV-pp65 CTLs

CMV-pp65 CTLs is a phase 2 stage product being developed by Atara Biotherapeutics for Cytomegalovirus. The current trial status is completed. This product is registered under clinical trial identifier NCT01646645. Target conditions include Cytomegalovirus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01646645Phase 2Completed

Competing Products

20 competing products in Cytomegalovirus

See all competitors
ProductCompanyStageHype Score
ASP0113 + PlaceboAstellas PharmaPhase 2
52
ASP0113 + PlaceboAstellas PharmaPhase 3
77
Letermovir oral granules + Letermovir tablet + Letermovir intravenousMerckPhase 2
52
Letermovir 240 mg Oral TabletMerckPhase 2
52
Letermovir tablet + Letermovir IVMerckPhase 3
77
LetermovirMerckPhase 1
33
LetermovirMerckApproved
85
Letermovir 480 MG [Prevymis]MerckPhase 2
52
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose IDMerckPhase 1
33
GanciclovirMerckPre-clinical
23
Letermovir + PlaceboMerckPhase 3
77
LetermovirMerckPhase 2
52
V160 + PlaceboMerckPhase 2
52
V160MerckPhase 1
33
LetermovirMerckPhase 3
77
LetermovirMerckPhase 3
77
Valganciclovir + GanciclovirRochePhase 3
77
Zidovudine + Didanosine + GanciclovirRochePhase 1
33
ValganciclovirRochePre-clinical
23
Foscarnet sodium + GanciclovirRochePhase 1
33

Other Products from Atara Biotherapeutics

EBV-specific T cells (EBV-CTLs)Phase 2
44
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)Phase 1/2
33
ATA188 + PlaceboPhase 1/2
33
WT1-sensitized T cellsPhase 1
25
cyclophosphamide + CAR T cellsPhase 1
25